Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin’s Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma

Written By Mukul Verma
Mukul Verma
Previous

Cancer Focus Fund Investing $4.5 Million in ImmunoGenesis to Support Drug Trial for Relapsed or Refractory Advanced Solid Tumors
Next

Ovarian cancer survivor: Immunotherapy clinical trial saved my life